Ascletis Pharma Stock Analysis
| ASCLF Stock | USD 2.10 0.12 6.06% |
Ascletis Pharma holds a debt-to-equity ratio of 0.001. Ascletis Pharma's financial risk is the risk to Ascletis Pharma stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Ascletis Pharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Ascletis Pharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Ascletis Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Ascletis Pharma's stakeholders.
For many companies, including Ascletis Pharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Ascletis Pharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Ascletis Pharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Ascletis Pharma's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Ascletis Pharma is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Ascletis Pharma to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Ascletis Pharma is said to be less leveraged. If creditors hold a majority of Ascletis Pharma's assets, the Company is said to be highly leveraged.
Ascletis Pharma is overvalued with Real Value of 1.95 and Hype Value of 2.1. The main objective of Ascletis Pharma pink sheet analysis is to determine its intrinsic value, which is an estimate of what Ascletis Pharma is worth, separate from its market price. There are two main types of Ascletis Pharma's stock analysis: fundamental analysis and technical analysis.
The Ascletis Pharma pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ascletis Pharma's ongoing operational relationships across important fundamental and technical indicators.
Ascletis |
Ascletis Pink Sheet Analysis Notes
About 67.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.58. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ascletis Pharma recorded a loss per share of 0.03. The entity had not issued any dividends in recent years. Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the Peoples Republic of China. Ascletis Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 266 people.The quote for Ascletis Pharma is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Ascletis Pharma please contact the company at 86 571 8538 9730 or go to https://www.ascletis.com.Ascletis Pharma Investment Alerts
| Ascletis Pharma is way too risky over 90 days horizon | |
| Ascletis Pharma appears to be risky and price may revert if volatility continues | |
| Ascletis Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 76.88 M. Net Loss for the year was (199.02 M) with profit before overhead, payroll, taxes, and interest of 39.17 M. | |
| Ascletis Pharma has accumulated about 2.5 B in cash with (146.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are held by company insiders |
Ascletis Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 672.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ascletis Pharma's market, we take the total number of its shares issued and multiply it by Ascletis Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Ascletis Profitablity
The company has Profit Margin (PM) of (2.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.11.Technical Drivers
As of the 11th of February 2026, Ascletis Pharma shows the risk adjusted performance of 0.1421, and Mean Deviation of 3.58. Ascletis Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascletis Pharma jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Ascletis Pharma is priced correctly, providing market reflects its regular price of 2.1 per share. Please also double-check Ascletis Pharma total risk alpha, which is currently at 0.4194 to validate the company can sustain itself at a future point.Ascletis Pharma Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Ascletis Pharma price series with the more recent values given greater weights.
Ascletis Pharma Predictive Daily Indicators
Ascletis Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ascletis Pharma pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 2.1 | |||
| Day Typical Price | 2.1 | |||
| Price Action Indicator | 0.06 | |||
| Period Momentum Indicator | 0.12 |
Ascletis Pharma Forecast Models
Ascletis Pharma's time-series forecasting models are one of many Ascletis Pharma's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ascletis Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Ascletis Pharma Debt to Cash Allocation
Many companies such as Ascletis Pharma, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Ascletis Pharma has accumulated 2.75 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Ascletis Pharma has a current ratio of 28.35, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Ascletis Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Ascletis Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ascletis Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ascletis to invest in growth at high rates of return. When we think about Ascletis Pharma's use of debt, we should always consider it together with cash and equity.Ascletis Pharma Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Ascletis Pharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Ascletis Pharma, which in turn will lower the firm's financial flexibility.About Ascletis Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Ascletis Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ascletis shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Ascletis Pharma. By using and applying Ascletis Pink Sheet analysis, traders can create a robust methodology for identifying Ascletis entry and exit points for their positions.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the Peoples Republic of China. Ascletis Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 266 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Ascletis Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Complementary Tools for Ascletis Pink Sheet analysis
When running Ascletis Pharma's price analysis, check to measure Ascletis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascletis Pharma is operating at the current time. Most of Ascletis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascletis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascletis Pharma's price. Additionally, you may evaluate how the addition of Ascletis Pharma to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |